Published in Biochem Pharmacol on May 05, 2010
Mutant p53: one name, many proteins. Genes Dev (2012) 4.33
p53 regulation by ubiquitin. FEBS Lett (2011) 1.51
Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy (2011) 1.29
CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Mol Interv (2011) 1.14
p53 Gene repair with zinc finger nucleases optimised by yeast 1-hybrid and validated by Solexa sequencing. PLoS One (2011) 1.04
Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. Cancer Res (2013) 1.02
Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opin Ther Targets (2012) 1.01
Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance. Adv Cancer Res (2013) 0.99
p53 Acetylation: Regulation and Consequences. Cancers (Basel) (2014) 0.97
Paracrine apoptotic effect of p53 mediated by tumor suppressor Par-4. Cell Rep (2014) 0.96
Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis. Nat Chem Biol (2014) 0.94
Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence. Lung Cancer (2013) 0.93
CLCA2, a target of the p53 family, negatively regulates cancer cell migration and invasion. Cancer Biol Ther (2012) 0.91
Rapid and Sensitive Detection of p53 Based on DNA-Protein Binding Interactions Using Silver Nanoparticle Films and Microwave Heating. Nano Biomed Eng (2014) 0.87
P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation. World J Gastroenterol (2015) 0.86
Tumor microenvironment: a new treatment target for cancer. ISRN Biochem (2014) 0.86
Transcriptional regulation of thymine DNA glycosylase (TDG) by the tumor suppressor protein p53. Cell Cycle (2012) 0.85
What is recent in pancreatic cancer immunotherapy? Biomed Res Int (2012) 0.84
The tumor suppressor gene Trp53 protects the mouse lens against posterior subcapsular cataracts and the BMP receptor Acvr1 acts as a tumor suppressor in the lens. Dis Model Mech (2011) 0.83
Resuscitating wild-type p53 expression by disrupting ceramide glycosylation: a novel approach to target mutant p53 tumors. Cancer Res (2011) 0.83
Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis. Chem Biol (2015) 0.82
Ceramide modulates pre-mRNA splicing to restore the expression of wild-type tumor suppressor p53 in deletion-mutant cancer cells. Biochim Biophys Acta (2014) 0.81
mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction. PLoS One (2011) 0.81
Structural determinants of benzodiazepinedione/peptide-based p53-HDM2 inhibitors using 3D-QSAR, docking and molecular dynamics. J Mol Model (2011) 0.80
Ribosomal protein S27-like in colorectal cancer: a candidate for predicting prognoses. PLoS One (2013) 0.80
Menadione induces the formation of reactive oxygen species and depletion of GSH-mediated apoptosis and inhibits the FAK-mediated cell invasion. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.78
The role of tumor microenvironment in therapeutic resistance. Oncotarget (2016) 0.78
Quercetin-3-O-(2″-galloyl)-α-L-rhamnopyranoside attenuates cholesterol oxidation product-induced apoptosis by suppressing NF-κB-mediated cell death process in differentiated PC12 cells. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.77
Overexpression of p53 activated by small activating RNA suppresses the growth of human prostate cancer cells. Onco Targets Ther (2016) 0.77
p53 and mitochondrial dysfunction: novel insight of neurodegenerative diseases. J Bioenerg Biomembr (2016) 0.77
Inhibition of human lung cancer cell proliferation and survival by wine. Cancer Cell Int (2014) 0.77
Diarylheptanoid hirsutenone enhances apoptotic effect of TRAIL on epithelial ovarian carcinoma cell lines via activation of death receptor and mitochondrial pathway. Invest New Drugs (2010) 0.77
Harnessing the apoptotic programs in cancer stem-like cells. EMBO Rep (2015) 0.77
Hyperthermia: How Can It Be Used? Oman Med J (2016) 0.76
Rotundarpene prevents TRAIL-induced apoptosis in human keratinocytes by suppressing the caspase-8- and Bid-pathways and the mitochondrial pathway. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75
MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53. Oncotarget (2016) 0.75
Three-dimensional apoptotic nuclear behavior analyzed by means of Field Emission in Lens Scanning Electron Microscope. Eur J Histochem (2015) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Overview of cell death signaling pathways. Cancer Biol Ther (2005) 4.22
An iron delivery pathway mediated by a lipocalin. Mol Cell (2002) 3.38
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Critical role for Daxx in regulating Mdm2. Nat Cell Biol (2006) 2.96
TRAIL and apoptosis induction by TNF-family death receptors. Oncogene (2003) 2.75
P53 and radiation responses. Oncogene (2003) 2.52
Retracted GAMT, a p53-inducible modulator of apoptosis, is critical for the adaptive response to nutrient stress. Mol Cell (2009) 2.30
The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res (2010) 2.13
Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med (2013) 2.06
p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol (2013) 2.06
Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther (2003) 1.92
The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther (2002) 1.91
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol (2004) 1.90
Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol Cell Biol (2006) 1.88
BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol (2002) 1.84
Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol (2003) 1.83
Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci U S A (2006) 1.80
Tissue-specific induction of p53 targets in vivo. Cancer Res (2002) 1.79
TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets (2010) 1.65
Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem (2004) 1.59
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res (2007) 1.58
CARP-2 is an endosome-associated ubiquitin ligase for RIP and regulates TNF-induced NF-kappaB activation. Curr Biol (2008) 1.58
DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol (2005) 1.55
Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell (2004) 1.54
Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol (2003) 1.54
Restoration of p53 to limit tumor growth. Curr Opin Oncol (2008) 1.52
The cyclin-dependent kinase inhibitor butyrolactone is a potent inhibitor of p21 (WAF1/CIP1 expression). Cell Cycle (2002) 1.45
Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget (2011) 1.43
Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol Ther (2009) 1.43
TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest (2008) 1.41
Mcl-1: a gateway to TRAIL sensitization. Cancer Res (2008) 1.41
Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis (2009) 1.40
Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther (2005) 1.38
Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: an effective multi-faceted targeting of the tumor-cell phenotype? Cancer Biol Ther (2004) 1.38
TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther (2008) 1.34
Microarray analysis of p53 target gene expression patterns in the spleen and thymus in response to ionizing radiation. Cancer Biol Ther (2003) 1.32
Protective effects of dietary antioxidants on proton total-body irradiation-mediated hematopoietic cell and animal survival. Radiat Res (2009) 1.31
Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci U S A (2002) 1.30
Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem (2004) 1.29
Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res (2004) 1.28
BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol (2002) 1.28
Effects of low confluency, serum starvation and hypoxia on the side population of cancer cell lines. Cell Cycle (2007) 1.28
Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol (2005) 1.27
Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol (2008) 1.25
Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol (2003) 1.25
Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia (2002) 1.24
Restoring p53-dependent tumor suppression. Cancer Biol Ther (2003) 1.24
Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem (2011) 1.23
Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res (2004) 1.22
An integrated, multiparametric flow cytometry chip using "microfluidic drifting" based three-dimensional hydrodynamic focusing. Biomicrofluidics (2012) 1.22
Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther (2007) 1.22
Circulating Tumor Cells and Colorectal Cancer. Curr Colorectal Cancer Rep (2010) 1.21
Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Res (2006) 1.20
The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle (2009) 1.18
ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest (2014) 1.16
Differentiation of normal skin and melanoma using high resolution hyperspectral imaging. Cancer Biol Ther (2006) 1.16
Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A (2003) 1.16
What are caspases 3 and 7 doing upstream of the mitochondria? Cancer Biol Ther (2006) 1.16
Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genet (2003) 1.14
ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell Cycle (2015) 1.14
Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis (2003) 1.13
Regulation of the human TRAIL gene. Cancer Biol Ther (2012) 1.12
Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle (2002) 1.12
Suppression of caspase-8- and -10-associated RING proteins results in sensitization to death ligands and inhibition of tumor cell growth. Proc Natl Acad Sci U S A (2004) 1.10
p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Res (2006) 1.09
Invincible, but not invisible: imaging approaches toward in vivo detection of cancer stem cells. J Clin Oncol (2008) 1.08
Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle (2011) 1.07
Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin. Cancer Biol Ther (2005) 1.04
ERK and MDM2 prey on FOXO3a. Nat Cell Biol (2008) 1.04
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. Cancer Biol Ther (2013) 1.03
Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. Cancer Res (2013) 1.02
Acridine derivatives activate p53 and induce tumor cell death through Bax. Cancer Biol Ther (2005) 1.02
Cell cycle checkpoint control mechanisms that can be disrupted in cancer. Methods Mol Biol (2004) 1.02
Microarray expression profiling of p53-dependent transcriptional changes in an immortalized mouse embryo fibroblast cell line. Cancer Biol Ther (2003) 1.02
Targeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther Targets (2015) 1.02
CARPs are ubiquitin ligases that promote MDM2-independent p53 and phospho-p53ser20 degradation. J Biol Chem (2006) 1.01
Therapeutic targeting of the p53 pathway in cancer stem cells. Expert Opin Ther Targets (2012) 1.01
p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J Clin Endocrinol Metab (2005) 1.01
TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle (2008) 1.01
BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. J Biol Chem (2003) 1.00
Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med (2011) 0.99
Replication stress, defective S-phase checkpoint and increased death in Plk2-deficient human cancer cells. Cell Cycle (2007) 0.99
CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle (2013) 0.98
Multispectral fluorescence imaging. J Nucl Med (2009) 0.98
Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene (2002) 0.98
The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle (2011) 0.97
IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms. Cancer Biol Ther (2007) 0.97
Caspase 10 levels are increased following DNA damage in a p53-dependent manner. Cancer Biol Ther (2003) 0.97
Clinical implication of p53 mutation in lung cancer. Mol Biotechnol (2003) 0.96
Identification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic gene. J Biol Chem (2003) 0.96